Skip to main content

Advertisement

SpringerLink
Log in

Successful use of infliximab in the treatment of Reiter’s syndrome: a case report and discussion

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Reiter’s syndrome is one of the reactive forms of seronegative spondyloarthropathies. Various therapies used in the management of Reiter’s syndrome are nonsteroidal antiinflammatory drugs (NSAIDs), antibiotics, and disease-modifying antirheumatic drugs (DMARDs) such as sulfasalazine (SSZ) or methotrexate (MTX). There is only one case report of successful treatment of Reiter’s syndrome with tumor necrosis factor-α (TNF-α) blockers in human immunodeficiency virus (HIV) patient (Gaylis N, 2003, J Rheumatol 30(2):407–411 Feb). We hereby report a case of Reiter’s syndrome treated successfully with infliximab, an anti-TNF-α chimeric monoclonal antibody. A 28-year-old white male presented with painful swelling of right elbow and ankle joints, urethritis. and lesions involving skin of soles of feet and penis. Detailed work-up of sexually transmitted diseases (STDs), HIV, and systemic etiology were negative. Despite aggressive treatment with antibiotics, NSAIDS, prednisone, and MTX for 3 months, he had persistent synovitis and worsening of skin lesions. He was then treated with infliximab 200 mg intravenously at weeks 0, 2, 6, and 14 weeks which resulted in complete resolution of arthritis and skin lesions within 6 weeks of infliximab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Gaylis N (2003) Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 30(2):407–411 Feb

    PubMed  Google Scholar 

  2. Keat A (1983) Reiter’s syndrome and reactive arthritis in perspective. N Engl J Med 309:1606

    Article  PubMed  CAS  Google Scholar 

  3. Medina-Rodriguez F, Fraga A et al (1993) Sulfasalazine treatment in Reiter’s syndrome patients may not be sufficient (letter). Arthritis Rheum 36:726–727

    Article  PubMed  CAS  Google Scholar 

  4. Van der Heijde D, Braun J et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574 Aug 15

    Article  PubMed  CAS  Google Scholar 

  5. Chaudhari U, Gottlieb AB et al (2001) Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357:1842–1847

    Article  PubMed  CAS  Google Scholar 

  6. Van den Bosch F, Mielants H et al (2000) Crohn’s disease associated with spondyloarthropathy: effect of TNF-alpha blockade with infliximab on articular symptoms. Lancet 356(9244):1821–1822 Nov 25

    Article  PubMed  Google Scholar 

  7. Brandt J, Haibel H, Reddig J, Sieper J, Braun J (2002) Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29(1):118–122 Jan

    PubMed  CAS  Google Scholar 

  8. Keffer J, Probert L, Cazlaris H et al (1991) Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025–4031

    PubMed  CAS  Google Scholar 

  9. Williams RO, Feldmann M, Maini RN (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89:9784–9788

    Article  PubMed  CAS  Google Scholar 

  10. Danning CL, McInnes IB et al (2000) Macrophage-derived cytokine and nuclear factor kappa B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum 43:1244–1256

    Article  PubMed  CAS  Google Scholar 

  11. Austin LM, Ozawa M, Kikuchi T, Walters IB, Krueger JG (1999) The majority of epidermal T cells in psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiation bias is also measured in circulating blood T cells in psoriatic patients. J Invest Dermatol 113:752–759

    Article  PubMed  CAS  Google Scholar 

  12. Lange U, Teichmann J, Stracke H (2000) Correlation between plasma TNF-alpha, IGF-1, biochemical markers of bone metabolism,markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 5:507–511

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Rheumatology, University of Mississippi Medical center, 2500 N State Street, Jackson, MS, 39216, USA

    Himmat Gill & Vikas Majithia

Authors
  1. Himmat Gill
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vikas Majithia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Himmat Gill.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gill, H., Majithia, V. Successful use of infliximab in the treatment of Reiter’s syndrome: a case report and discussion. Clin Rheumatol 27, 121–123 (2008). https://doi.org/10.1007/s10067-007-0692-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0692-0

Keywords

Search

Navigation